109 related articles for article (PubMed ID: 15646067)
1. Viral phenotype and fitness.
Andreoni M
New Microbiol; 2004 Apr; 27(2 Suppl 1):71-6. PubMed ID: 15646067
[TBL] [Abstract][Full Text] [Related]
2. Replication capacity, biological phenotype, and drug resistance of HIV strains isolated from patients failing antiretroviral therapy.
Nicastri E; Sarmati L; d'Ettorre G; Palmisano L; Parisi SG; Uccella I; Rianda A; Concia E; Vullo V; Vella S; Andreoni M
J Med Virol; 2003 Jan; 69(1):1-6. PubMed ID: 12436471
[TBL] [Abstract][Full Text] [Related]
3. Study of the impact of HIV genotypic drug resistance testing on therapy efficacy.
Van Vaerenbergh K
Verh K Acad Geneeskd Belg; 2001; 63(5):447-73. PubMed ID: 11813503
[TBL] [Abstract][Full Text] [Related]
4. Can modulation of viral fitness represent a target for anti-HIV-1 strategies?
Clementi M
New Microbiol; 2004 Jul; 27(3):207-14. PubMed ID: 15460522
[TBL] [Abstract][Full Text] [Related]
5. HIV-1 reverse transcriptase inhibitor resistance mutations and fitness: a view from the clinic and ex vivo.
Martinez-Picado J; Martínez MA
Virus Res; 2008 Jun; 134(1-2):104-23. PubMed ID: 18289713
[TBL] [Abstract][Full Text] [Related]
6. HIV type 1 fitness evolution in antiretroviral-experienced patients with sustained CD4+ T cell counts but persistent virologic failure.
Prado JG; Parkin NT; Clotet B; Ruiz L; Martinez-Picado J
Clin Infect Dis; 2005 Sep; 41(5):729-37. PubMed ID: 16080097
[TBL] [Abstract][Full Text] [Related]
7. Impact of drug resistance genotypes on CD4+ counts and plasma viremia in heavily antiretroviral-experienced HIV-infected patients.
Rodes B; García F; Gutierrez C; Martinez-Picado J; Aguilera A; Saumoy M; Vallejo A; Domingo P; Dalmau D; Ribas MA; Blanco JL; Pedreira J; Perez-Elias MJ; Leal M; de Mendoza C; Soriano V;
J Med Virol; 2005 Sep; 77(1):23-8. PubMed ID: 16032728
[TBL] [Abstract][Full Text] [Related]
8. Changes in human immunodeficiency virus type 1 populations after treatment interruption in patients failing antiretroviral therapy.
Hance AJ; Lemiale V; Izopet J; Lecossier D; Joly V; Massip P; Mammano F; Descamps D; Brun-Vézinet F; Clavel F
J Virol; 2001 Jul; 75(14):6410-7. PubMed ID: 11413308
[TBL] [Abstract][Full Text] [Related]
9. Increased drug susceptibility of HIV-1 reverse transcriptase mutants containing M184V and zidovudine-associated mutations: analysis of enzyme processivity, chain-terminator removal and viral replication.
Naeger LK; Margot NA; Miller MD
Antivir Ther; 2001 Jun; 6(2):115-26. PubMed ID: 11491416
[TBL] [Abstract][Full Text] [Related]
10. Higher CD4+ T cell counts associated with low viral pol replication capacity among treatment-naive adults in early HIV-1 infection.
Barbour JD; Hecht FM; Wrin T; Segal MR; Ramstead CA; Liegler TJ; Busch MP; Petropoulos CJ; Hellmann NS; Kahn JO; Grant RM
J Infect Dis; 2004 Jul; 190(2):251-6. PubMed ID: 15216458
[TBL] [Abstract][Full Text] [Related]
11. Methods to determine HIV-1 ex vivo fitness.
Abraha A; Troyer RM; Quiñones-Mateu ME; Arts EJ
Methods Mol Biol; 2005; 304():355-68. PubMed ID: 16061989
[TBL] [Abstract][Full Text] [Related]
12. Emergence of HIV-1 drug resistance during antiretroviral treatment.
Rong L; Feng Z; Perelson AS
Bull Math Biol; 2007 Aug; 69(6):2027-60. PubMed ID: 17450401
[TBL] [Abstract][Full Text] [Related]
13. Competitive capacity of HIV-1 strains carrying M184I or Y181I drug-resistant mutations.
Li J; Li L; Li HP; Zhuang DM; Liu SY; Liu YJ; Bao ZY; Wang Z; Li JY
Chin Med J (Engl); 2009 May; 122(9):1081-6. PubMed ID: 19493444
[TBL] [Abstract][Full Text] [Related]
14. Mutations linked to drug resistance, human immunodeficiency virus type 1 biologic phenotype and their association with disease progression in children receiving nucleoside reverse transcriptase inhibitors.
Englund JA; Raskino C; Vavro C; Palumbo P; Ross LL; McKinney R; Nikolic-Djokic D; Colgrove RC; Baker CJ;
Pediatr Infect Dis J; 2004 Jan; 23(1):15-22. PubMed ID: 14743040
[TBL] [Abstract][Full Text] [Related]
15. In vivo emergence of drug-resistant mutations at less than 50 HIV-1 RNA copies/mL that are maintained at viral rebound in longitudinal plasma samples from human immunodeficiency virus type-1-infected patients on highly active antiretroviral therapy.
Elbeik T; Hoo BS; Campodonico ME; Dileanis J; Fay FF; Bortolozzi RL; Benetti MS; Fay OH; Marlowe N; Petrauskene O; Chernoff D; Smith L; Ng VL
J Hum Virol; 2001; 4(6):317-28. PubMed ID: 12082398
[TBL] [Abstract][Full Text] [Related]
16. Intra-host evolution of human immunodeficiency virus type 1 and viral fitness.
Clementi M; Canducci F; Bagnarelli P; Menzo S
New Microbiol; 2004 Apr; 27(2 Suppl 1):41-4. PubMed ID: 15646063
[TBL] [Abstract][Full Text] [Related]
17. Genotypic resistance and HIV-1 subtype in Brazilian children on dual and triple combination therapy.
Machado ES; Lambert JS; Watson DC; Afonso AO; da Cunha SM; Nogueira SA; Caride E; Oliveira RH; Sill AM; DeVico A; Tanuri A
J Clin Virol; 2004 May; 30(1):24-31. PubMed ID: 15072750
[TBL] [Abstract][Full Text] [Related]
18. New viral fitness test helps determine regimens.
AIDS Alert; 2002 Aug; 17(8):100-1. PubMed ID: 12647689
[TBL] [Abstract][Full Text] [Related]
19. Persistence of HIV-1 drug resistance mutations and emergence during antiretroviral treatment interruption: considerations from a clinical case.
Torti C; Moretti F; Uccelli MC; Tirelli V; Quiros-Roldan E; Gargiulo F; Carosi G
Med Sci Monit; 2003 Apr; 9(4):CS16-9. PubMed ID: 12709675
[TBL] [Abstract][Full Text] [Related]
20. Impact of clinical reverse transcriptase sequences on the replication capacity of HIV-1 drug-resistant mutants.
Dykes C; Fox K; Lloyd A; Chiulli M; Morse E; Demeter LM
Virology; 2001 Jul; 285(2):193-203. PubMed ID: 11437654
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
